hotspot -WSS

hotspot

author：fashion 2025-08-29 01:53:23 - browse：4754

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： STAT Summit: GSK CEO on pharma giant's new direction

hotspot

WSS

Will Ozempic

NIH confirmation hearing shows politicization of research

Long Covid research funding gets a major boost from NIH

Senate committee scrutinizes Medicare Advantage brokers

Eli Lilly expects to double planned employment in Boston center

Bernie Sanders gets little from pharma CEOs on drug prices

leisure time

hotspot

hotspot

Continuity nursing helped my family in our darkest PICU moments

Ebola vaccine can save some who are already sick, per new study

Medicare details structure of new drug price negotiation program

Studies point to risks of excluding people with obesity from drug trials

State Dept. review finds Biden bears some blame for Afghanistan failures

Latigo launches with $135 million for Vertex

Activists slam private health insurers over coverage restrictions

Websites selling Wegovy, Zepbound ingredients targeted by FDA

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

First Opinion Podcast: Long Covid needs a new approach

focus

The explosion of genetic testing requires a new approach

ACIP vaccine advisory panel sees its vacancies filled

Latigo launches with $135 million for Vertex

Studies point to risks of excluding people with obesity from drug trials

Congress considering partial increase for doctor pay in Medicare

Hospital price transparency does save money, advocate argues

leisure time

hotspot

explore

hotspot